Eph receptor signaling and ephrins

Cold Spring Harbor Perspectives in Biology

Volumn 5, Issue 9, 2013, Pages

  Lisabeth, Erika M ^a   Falivelli, Giulia ^a,b   Pasquale, Elena B ^a,c  

^a BURNHAM INSTITUTE   (United States)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPHRIN; EPHRIN RECEPTOR A1; RHO GUANINE NUCLEOTIDE BINDING PROTEIN;

ARTICLE; BIOLOGICAL MODEL; CELL COMMUNICATION; GENETICS; METABOLISM; MUTATION; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE; SIGNAL TRANSDUCTION;

CELL COMMUNICATION; EPHRINS; MODELS, BIOLOGICAL; MUTATION; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, EPHA1; RHO GTP-BINDING PROTEINS; SIGNAL TRANSDUCTION;

EID: 84883812678     PISSN: None     EISSN: 19430264     Source Type: Journal    
DOI: 10.1101/cshperspect.a009159     Document Type: Article

References (192)

1. Afshari F. T, Kwok JC, Fawcett JW. 2010. Astrocyte-produced ephrins inhibit Schwann cell migration via VAV2 signaling. J Neurosci 30: 4246-4255.
2. Antion M. D, Christie LA, Bond AM, Dalva MB, Contractor A. 2010. Ephrin-B3 regulates glutamate receptor signaling at hippocampal synapses. Mol Cell Neurosci 45: 378-388.
3. Argenzio E., Bange T, Oldrini B, Bianchi F, Peesari R, Mari S, Di Fiore PP, Mann M, Polo S. 2011. Proteomic snapshot of the EGF-induced ubiquitin network. Mol Syst Biol 7: 462.
4. ArvanitisD, Davy A. 2008. Eph/ephrin signaling:Networks. Genes Dev 22: 416-429.
5. Arvanitis D. N, Jungas T, Behar A, Davy A. 2010. Ephrin-B1 reverse signaling controls a posttranscriptional feedback mechanism via miR-124. Mol Cell Biol 30: 2508-2517.
6. Astin J. W, Batson J, Kadir S, Charlet J, Persad RA, Gillatt D, Oxley J. D, Nobes CD. 2010. Competition amongst Eph receptors regulates contact inhibition of locomotion and invasiveness in prostate cancer cells. Nat Cell Biol 12: 1194-1204.
7. Attwood B. K, Bourgognon JM, Patel S, Mucha M, Schiavon E, Skrzypiec AE, Young KW, Shiosaka S, Korostynski M, Piechota M., et al. 2011. Neuropsin cleaves EphB2 in the amygdala to control anxiety. Nature 473: 372-375.
8. Baba A., Akagi K, Takayanagi M, Flanagan JG, Kobayashi T, Hattori M. 2009. Fyn tyrosine kinase regulates the surface expression of glycosylphosphatidylinositol-linked ephrin via the modulation of sphingomyelin metabolism. J Biol Chem 284: 9206-9214.
9. Bartley T. D, Hunt RW, Welcher AA, Boyle WJ, Parker VP, Lindberg R. A, Lu HS, Colombero AM, Elliott RL, Guthrie BA. 1994. B61 is a ligand for the ECK receptor proteintyrosine kinase. Nature 368: 558-560.
10. Barton WA, Dalton AC, Seegar TCM, Himanen JP, Nikolov DB. 2013. Tie2 and Eph receptor tyrosine kinase activation and signaling. Cold Spring Harb Perspect Biol doi: 10.1101/cshperspect.a009142.
11. Beg A. A, Sommer JE, Martin JH, Scheiffele P. 2007. a2-Chimaerin is an essential EphA4 effector in the assembly of neuronal locomotor circuits. Neuron 55: 768-778.
12. Bhushan L., Kandpal RP. 2011. EphB6 receptor modulates microRNAprofile of breast carcinoma cells. PLoSONE6: e22484.
13. Binns K. L, Taylor PP, Sicheri F, Pawson T, Holland SJ. 2000. Phosphorylation of tyrosine residues in the kinase domain and juxtamembrane region regulates the biological and catalytic activities of Eph receptors. Mol Cell Biol 20: 4791-4805.
14. Bohme B., VandenBos T, Cerretti DP, Park LS, Holtrich U, Rubsamen-Waigmann H, Strebhardt K. 1996. Cell-cell adhesion mediated by binding of membrane-anchored ligand LERK-2 to the EPH-related receptor human embryonal kinase 2 promotes tyrosine kinase activity. J Biol Chem 271: 24747-24752.
15. Bonanomi D., Chivatakarn O, Bai G, Abdesselem H, Lettieri K, Marquardt T, Pierchala BA, Pfaff SL. 2012. Ret is a multifunctional coreceptor that integrates diffusibleand contact-axon guidance signals. Cell 148: 568-582.
16. Bong Y. S, Lee HS, Carim-Todd L, Mood K, Nishanian TG, Tessarollo L., Daar IO. 2007. ephrin-B1 signals from the cell surface to the nucleus by recruitment of STAT3. Proc Natl Acad Sci 104: 17305-17310.
17. Bouzioukh F., Wilkinson GA, Adelmann G, Frotscher M, Stein V., Klein R. 2007. Tyrosine phosphorylation sites in ephrin-B2 are required for hippocampal long-term potentiation but not long-term depression. J Neurosci 27: 11279-11288.
18. Brantley-Sieders DM, Zhuang G, HicksD, FangWB, Hwang Y, Cates JM, Coffman K, JacksonD, Bruckheimer E, Muraoka-Cook R. S, et al. 2008. The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling. J Clin Invest 118: 64-78.
19. Bush J. O, Soriano P. 2009. Ephrin-B1 regulates axon guidance by reverse signaling through a PDZ-dependent mechanism. Genes Dev 23: 1586-1599.
20. Bush J. O, Soriano P. 2010. Ephrin-B1 forward signaling regulates craniofacial morphogenesis by controlling cell proliferation across Eph-ephrin boundaries. Genes Dev 24: 2068-2080.
21. Bush J. O, Soriano P. 2012. Eph/ephrin signaling: Genetic, phosphoproteomic, and transcriptomic approaches. Semin Cell Dev Biol 23: 26-34.
22. Campbell T. N, Attwell S, Arcellana-Panlilio M, Robbins SM. 2006. Ephrin-A5 expression promotes invasion and transformation of murine fibroblasts. Biochem Biophys Res Commun 350: 623-628.
23. Carmona M. A, Murai KK, Wang L, Roberts AJ, Pasquale EB. 2009. Glial ephrin-A3 regulates hippocampal dendritic spine morphology and glutamate transport. Proc Natl Acad Sci 106: 12524-12529.
24. Carvalho R. F, Beutler M, Marler KJ, Knoll B, Becker-Barroso E, Heintzmann R, Ng T, Drescher U. 2006. Silencing of EphA3 through a cis interaction with ephrin-A5. Nat Neurosci 9: 322-330.
25. Chandarlapaty S., Sawai A, Scaltriti M, Rodrik-Outmezguine V, Grbovic-Huezo O, Serra V, Majumder PK, Baselga J, Rosen N. 2011. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 19: 58-71.
26. Chang Q., Jorgensen C, Pawson T, Hedley DW. 2008. Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer. Br J Cancer 99: 1074-1082.
27. Chiarugi P., Taddei ML, Schiavone N, Papucci L, Giannoni E, Fiaschi T., Capaccioli S, Raugei G, Ramponi G. 2004. LMW-PTP is a positive regulator of tumor onset and growth. Oncogene 23: 3905-3914.
28. Cisse M., Halabisky B, Harris J, Devidze N, Dubal DB, Sun B, Orr A., Lotz G, Kim DH, Hamto P, et al. 2011. Reversing EphB2 depletion rescues cognitive functions in Alzheimer model. Nature 469: 47-52.
29. Cowan C. A, Henkemeyer M. 2001. The SH2/SH3 adaptor Grb4 transduces B-ephrin reverse signals. Nature 413: 174-179.
30. Cowan C. W, Shao YR, Sahin M, Shamah SM, Lin MZ, Greer PL, Gao S, Griffith EC, Brugge JS, Greenberg ME. 2005. Vav family GEFs link activated Ephs to endocytosis and axon guidance. Neuron 46: 205-217.
31. Dail M., Richter M, Godement P, Pasquale EB. 2006. Eph receptors inactivate R-Ras through different mechanisms to achieve cell repulsion. J Cell Sci 119: 1244-1254.
32. Davy A., Gale NW, Murray EW, Klinghoffer RA, Soriano P, Feuerstein C., Robbins SM. 1999. Compartmentalized signaling by GPI-anchored ephrin-A5 requires the Fyn tyrosine kinase to regulate cellular adhesion. Genes Dev 13: 3125-3135.
33. Davy A., Feuerstein C, Robbins SM. 2000. Signaling within a caveolae-like membrane microdomain in human neuroblastoma cells in response to fibroblast growth factor. J Neurochem 74: 676-683.
34. Davy A., Bush JO, Soriano P. 2006. Inhibition of gap junction communication at ectopic Eph/ephrin boundaries underlies craniofrontonasal syndrome. PLoS Biol 4: e315.
35. Ding L., Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K., Sougnez C, Greulich H, Muzny DM, Morgan MB, et al. 2008. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455: 1069-1075.
36. Du J., Fu C, Sretavan DW. 2007. Eph/ephrin signaling as a potential therapeutic target after central nervous system injury. Curr Pharm Des 13: 2507-2518.
37. Elowe S., Holland SJ, Kulkarni S, Pawson T. 2001. Downregulation of the Ras-mitogen-activated protein kinase pathway by the EphB2 receptor tyrosine kinase is required for ephrin-induced neurite retraction. Mol Cell Biol 21: 7429-7441.
38. Essmann C. L, Martinez E, Geiger JC, Zimmer M, Traut MH, Stein V., Klein R, Acker-Palmer A. 2008. Serine phosphorylation of ephrin-B2 regulates trafficking of synaptic AMPA receptors. Nat Neurosci 11: 1035-1043.
39. Faoro L., Singleton PA, Cervantes GM, Lennon FE, Choong NW, Kanteti R, Ferguson BD, Husain AN, Tretiakova MS, Ramnath N., et al. 2010. EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation. J Biol Chem 285: 18575-18585.
40. Fasen K., Cerretti DP, Huynh-Do U. 2008. Ligand binding induces Cbl-dependent EphB1 receptor degradation through the lysosomal pathway. Traffic 9: 251-266.
41. Filosa A., Paixao S, Honsek SD, Carmona MA, Becker L, Feddersen B., Gaitanos L, Rudhard Y, Schoepfer R, Klopstock T, et al. 2009. Neuron-glia communication via EphA4/ephrin-A3 modulates LTP through glial glutamate transport. Nat Neurosci 12: 1285-1292.
42. Fu W. Y, Chen Y, Sahin M, Zhao XS, Shi L, Bikoff JB, Lai KO, Yung W. H, Fu AK, Greenberg ME, et al. 2007. Cdk5 regulates EphA4-mediated dendritic spine retraction through an ephexin1-dependent mechanism. NatNeurosci 10: 67-76.
43. Gale N. W, Flenniken A, Compton DC, Jenkins N, Copeland NG, Gilbert DJ, Davis S, Wilkinson DG, Yancopoulos GD. 1996. Elk-L3, a novel transmembrane ligand for the Eph family of receptor tyrosine kinases, expressed in embryonic floor plate, roof plate and hindbrain segments. Oncogene 13: 1343-1352.
44. Genander M., Frisen J. 2010. Ephrins and Eph receptors in stem cells and cancer. Curr Opin Cell Biol 22: 611-616.
45. Georgakopoulos A., Litterst C, Ghersi E, Baki L, Xu C, Serban G, Robakis NK. 2006. Metalloproteinase/Presenilin1 processing of ephrin-B regulates EphB-induced Src phosphorylation and signaling. EMBO J 25: 1242-1252.
46. Georgakopoulos A., Xu J, Xu C, Mauger G, Barthet G, Robakis NK. 2011. Presenilin1/g-secretase promotes the EphB2-induced phosphorylation of ephrin-B2 by regulating phosphoprotein associated with glycosphingolipid-enriched microdomains/Csk binding protein. FASEB J 25: 3594-3604.
47. Goh LK, Sorkin A. 2013. Endocytosis of receptor tyrosine kinases. Cold Spring Harb Perspect Biol doi: 10.1101/ cshperspect.a017459.
48. Gopal U., Bohonowych JE, Lema-Tome C, Liu A, Garrett-Mayer E., Wang B, Isaacs JS. 2011. A novel extracellular Hsp90 mediated co-receptor function for LRP1 regulates EphA2-dependent glioblastoma cell invasion. PLoS ONE 6: e17649.
49. Greulich H., Pollock PM. 2011. Targeting mutant fibroblast growth factor receptors in cancer. Trends Mol Med 17: 283-292.
50. Haj F. G, Sabet O, Kinkhabwala A, Wimmer-Kleikamp S, Roukos V., Han HM, Grabenbauer M, Bierbaum M, Antony C, Neel BG, et al. 2012. Regulation of signaling at regions of cell-cell contact by endoplasmic reticulumbound protein-tyrosine phosphatase 1B. PLoS ONE 7: e36633.
51. Harada K., Hiramoto-Yamaki N, Negishi M, Katoh H. 2011. Ephexin4 and EphA2 mediate resistance to anoikis through RhoG and phosphatidylinositol 3-kinase. Exp Cell Res 317: 1701-1713.
52. Hattori M., Osterfield M, Flanagan JG. 2000. Regulated cleavage of a contact-mediated axon repellent. Science 289: 1360-1365.
53. Heasman S. J, Ridley AJ. 2008. Mammalian Rho GTPases: New insights into their functions from in vivo studies. Nat Rev Mol Cell Biol 9: 690-701.
54. Himanen J. P, Yermekbayeva L, Janes PW, Walker JR, Xu K, Atapattu L., Rajashankar KR, Mensinga A, Lackmann M, Nikolov D. B, et al. 2010. Architecture of Eph receptor clusters. Proc Natl Acad Sci 107: 10860-10865.
55. Hiramoto-Yamaki N, Takeuchi S, Ueda S, Harada K, Fujimoto S, Negishi M, Katoh H. 2010. Ephexin4 and EphA2 mediate cell migration through a RhoG-dependent mechanism. J Cell Biol 190: 461-477.
56. Holen H. L, Shadidi M, Narvhus K, Kjosnes O, Tierens A, Aasheim H.C. 2008. Signaling through ephrin-A ligand leads to activation of Src-family kinases, Akt phosphorylation, and inhibition of antigen receptor-induced apoptosis. J Leukoc Biol 84: 1183-1191.
57. Holen H. L, Zernichow L, Fjelland KE, Evenroed IM, Prydz K, Tveit H, Aasheim HC. 2011. Ephrin-B3 binds to a sulfated cell-surface receptor. Biochem J 433: 215-223.
58. Hollingworth P., Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo M. M, Abraham R, Hamshere ML, Pahwa JS, Moskvina V., et al. 2011. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2APare associated with Alzheimer's disease. Nat Genet 43: 429-435.
59. Holmberg J., Clarke DL, Frisen J. 2000. Regulation of repulsion versus adhesion by different splice forms of an Eph receptor. Nature 408: 203-206.
60. Holmberg J., Armulik A, Senti KA, Edoff K, Spalding K, Momma S., Cassidy R, Flanagan JG, Frisen J. 2005. Ephrin-A2 reverse signaling negatively regulates neural progenitor proliferation and neurogenesis. Genes Dev 19: 462-471.
61. Hornberger M. R, Dutting D, Ciossek T, Yamada T, Handwerker C, Lang S, Weth F, Huf J, Wessel R, Logan C, et al. 1999. Modulation of EphA receptor function by coexpressed ephrin-A ligands on retinal ganglion cell axons. Neuron 22: 731-742.
62. Huang X, WuD, Jin H, StupackD, Wang JY. 2008. Induction of cell retraction by the combined actions of Abl-CrkII and Rho-ROCK1 signaling. J Cell Biol 183: 711-723.
63. Hunter S. G, Zhuang G, Brantley-Sieders D, Swat W, Cowan CW, Chen J. 2006. Essential role of vav family guanine nucleotide exchange factors in epha receptor-mediated angiogenesis. Mol Cell Biol 26: 4830-4842.
64. Huusko P., Ponciano-Jackson D, Wolf M, Kiefer JA, Azorsa DO, Tuzmen S, Weaver D, Robbins C, Moses T, Allinen M, et al. 2004. Nonsense-mediated decay microarray analysis identifies mutations of EPHB2 in human prostate cancer. Nat Genet 36: 979-983.
65. Ikeda M., Tomita Y, Mouri A, Koga M, Okochi T, Yoshimura R, Yamanouchi Y, Kinoshita Y, Hashimoto R, Williams HJ, et al. 2010. Identification of novel candidate genes for treatment response to risperidone and susceptibility for schizophrenia: Integrated analysis among pharmacogenomics, mouse expression, and genetic case-control association approaches. Biol Psychiatry 67: 263-269.
66. Inoue E., Deguchi-Tawarada M, Togawa A, Matsui C, Arita K, Katahira-Tayama S, Sato T, Yamauchi E, Oda Y, Takai Y. 2009. Synaptic activity prompts g-secretase-mediated cleavage of EphA4 and dendritic spine formation. J Cell Biol 185: 551-564.
67. Irie F., Yamaguchi Y. 2002. EphB receptors regulate dendritic spine development via intersectin, Cdc42 and N-WASP. Nat Neurosci 5: 1117-1118.
68. Irie F., Okuno M, Matsumoto K, Pasquale EB, Yamaguchi Y. 2008. Heparan sulfate regulates ephrin-A3/EphA receptor signaling. Proc Natl Acad Sci 105: 12307-12312.
69. Iwasato T., Katoh H, Nishimaru H, Ishikawa Y, Inoue H, Saito Y. M, Ando R, Iwama M, Takahashi R, Negishi M, et al. 2007. Rac-GAP a-chimerin regulates motor-circuit formation as a key mediator of ephrin-B3/EphA4 forward signaling. Cell 130: 742-753.
70. Janes P. W, Saha N, Barton WA, Kolev MV, Wimmer-Kleikamp SH, Nievergall E, Blobel CP, Himanen JP, Lackmann M, Nikolov DB. 2005. Adam meets Eph: An ADAM substrate recognition module acts as a molecular switch for ephrin cleavage in trans. Cell 123: 291-304.
71. Janes P. W, Wimmer-Kleikamp SH, Frangakis AS, Treble K, Griesshaber B., SabetO, Grabenbauer M, Ting AY, Saftig P, Bastiaens P. I, et al. 2009. Cytoplasmic relaxation of active Eph controls ephrin shedding by ADAM10. PLoS Biol 7: e1000215.
72. Janes P. W, Griesshaber B, Atapattu L, Nievergall E, Hii LL, Mensinga A., Chheang C, Day BW, Boyd AW, Bastiaens PI, et al. 2011. Eph receptor function is modulated by heterooligomerization of A and B type Eph receptors. J Cell Biol 195: 1033-1045.
73. Ji X. D, Li G, Feng YX, Zhao JS, Li JJ, Sun ZJ, Shi S, Deng YZ, Xu J. F, Zhu YQ, et al. 2011. EphB3 is overexpressed in nonsmall-cell lung cancer and promotes tumor metastasis by enhancing cell survival and migration. Cancer Res 71: 1156-1166.
74. Jorgensen C., Sherman A, Chen GI, Pasculescu A, Poliakov A, Hsiung M., Larsen B, Wilkinson DG, Linding R, Pawson T. 2009. Cell-specific information processing in segregating populations of Eph receptor ephrin-expressing cells. Science 326: 1502-1509.
75. Jun G., Guo H, Klein BE, Klein R, Wang JJ, Mitchell P, Miao H, Lee KE, Joshi T, Buck M, et al. 2009. EPHA2 is associated with age-related cortical cataract in mice and humans. PLoS Genet 5: e1000584.
76. Kao T. J, Kania A. 2011. Ephrin-mediated cis-attenuation of Eph receptor signaling is essential for spinal motor axon guidance. Neuron 71: 76-91.
77. Khodayari N., Mohammed KA, Goldberg EP, Nasreen N. 2011. Ephrin-A1 inhibits malignant mesothelioma tumor growth via let-7 microRNA-mediated repression of the RAS oncogene. Cancer Gene Ther 18: 806-816.
78. Kikawa K. D, Vidale DR, Van Etten RL, Kinch MS. 2002. Regulation of the EphA2 kinase by the low molecular weight tyrosine phosphatase induces transformation. J Biol Chem 277: 39274-39279.
79. Klein R. 2009. Bidirectional modulation of synaptic functions by Eph/ephrin signaling. Nat Neurosci 12: 15-20.
80. Konstantinova I., Nikolova G, Ohara-Imaizumi M, Meda P, Kucera T., Zarbalis K, WurstW, Nagamatsu S, Lammert E. 2007. EphA-Ephrin-A-mediated b cell communication regulates insulin secretion from pancreatic islets. Cell 129: 359-370.
81. Lackmann M., Boyd AW. 2008. Eph, a protein family coming of age:More confusion, insight, or complexity? Sci Signal 1: re2.
82. Lai K. O, Chen Y, Po HM, Lok KC, Gong K, Ip NY. 2004. Identification of the Jak/Stat proteins as novel downstream targets of EphA4 signaling in muscle: Implications in the regulation of acetylcholinesterase expression. J Biol Chem 279: 13383-13392.
83. Larsen A. B, Pedersen MW, Stockhausen MT, Grandal MV, van Deurs B, Poulsen HS. 2007. Activation of the EGFR gene target EphA2 inhibits epidermal growth factor-induced cancer cell motility. Mol Cancer Res 5: 283-293.
84. Lee J. C, Vivanco I, Beroukhim R, Huang JH, Feng WL, De-Biasi R. M, Yoshimoto K, King JC, Nghiemphu P, Yuza Y, et al. 2006. Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med 3: e485.
85. Lee H. S, Nishanian TG, Mood K, Bong YS, Daar IO. 2008. Ephrin-B1 controls cell-cell junctions through the Par polarity complex. Nat Cell Biol 10: 979-986.
86. Lee H. J, Hota PK, Chugha P, Guo H, Miao H, Zhang L, Kim SJ, Stetzik L, Wang BC, Buck M. 2012. NMR Structure of a heterodimeric SAM:SAM complex: Characterization and manipulation of epha2 binding reveal new cellular functions of SHIP2. Structure 20: 41-55.
87. Lesnick T. G, Sorenson EJ, Ahlskog JE, Henley JR, Shehadeh L, Papapetropoulos S, Maraganore DM. 2008. Beyond Parkinson disease: Amyotrophic lateral sclerosis and the axon guidance pathway. PLoS ONE 3: e1449.
88. Li J. J, Liu DP, Liu GT, Xie D. 2009. Ephrin-A5 acts as a tumor suppressor in glioma by negative regulation of epidermal growth factor receptor. Oncogene 28: 1759-1768.
89. Li G., Ji XD, Gao H, Zhao JS, Xu JF, Sun ZJ, Deng YZ, Shi S, Feng Y. X, Zhu YQ, et al. 2012. EphB3 suppresses nonsmall-cell lung cancer metastasis via a PP2A/RACK1/ Akt signalling complex. Nat Commun 3: 667.
90. Lim Y. S, McLaughlin T, Sung TC, Santiago A, Lee KF, O'Leary DD. 2008. p75(NTR) mediates ephrin-A reverse signaling required for axon repulsion and mapping. Neuron 59: 746-758.
91. Lisabeth E. M, Fernandez C, Pasquale EB. 2012. Cancer somatic mutations disrupt functions of the EphA3 receptor tyrosine kinase through multiple mechanisms. Biochemistry 51: 1464-1475.
92. Litterst C., Georgakopoulos A, Shioi J, Ghersi E, Wisniewski T, Wang R, Ludwig A, Robakis NK. 2007. Ligand binding and calcium influx induce distinct ectodomain/g-secretase-processing pathways of EphB2 receptor. J Biol Chem 282: 16155-16163.
93. Lu Q., Sun EE, Klein RS, Flanagan JG. 2001. Ephrin-B reverse signaling is mediated by a novel PDZ-RGS protein and selectively inhibits G protein-coupled chemoattraction. Cell 105: 69-79.
94. Macrae M., Neve RM, Rodriguez-Viciana P, Haqq C, Yeh J, Chen C., Gray JW, McCormick F. 2005. A conditional feedback loop regulates Ras activity through EphA2. Cancer Cell 8: 111-118.
95. Maddigan A., Truitt L, Arsenault R, Freywald T, Allonby O, Dean J., Narendran A, Xiang J, Weng A, Napper S, et al. 2011. EphB receptors trigger Akt activation and suppress Fas receptor-induced apoptosis in malignant T lymphocytes. J Immunol 187: 5983-5994.
96. Makarov R., Steiner B, Gucev Z, Tasic V, Wieacker P, Wieland I. 2010. The impact of CFNS-causing EFNB1 mutations on ephrin-B1 function. BMC Med Genet 11: 98.
97. Makinen T., Adams RH, Bailey J, Lu Q, Ziemiecki A, Alitalo K, Klein R, Wilkinson GA. 2005. PDZ interaction site in ephrin-B2 is required for the remodeling of lymphatic vasculature. Genes Dev 19: 397-410.
98. Manning B. D, Cantley LC. 2007. AKT/PKB signaling: Navigating downstream. Cell 129: 1261-1274.
99. Margolis S. S, Salogiannis J, Lipton DM, Mandel-Brehm C, Wills Z. P, Mardinly AR, Hu L, Greer PL, Bikoff JB, HoHY, et al. 2010. EphB-mediated degradation of the RhoAGEF Ephexin5 relieves a developmental brake on excitatory synapse formation. Cell 143: 442-455.
100. Marler K. J, Becker-Barroso E, Martinez A, Llovera M, Wentzel C, Poopalasundaram S, Hindges R, Soriano E, Comella J, Drescher U. 2008. ATrkB/Ephrin-A interaction controls retinal axon branching and synaptogenesis. J Neurosci 28: 12700-12712.
101. Marler K. J, Poopalasundaram S, Broom ER, Wentzel C, Drescher U. 2010. Pro-neurotrophins secreted from retinal ganglion cell axons are necessary for ephrin-Ap75NTR-mediated axon guidance. Neural Dev 5: 30.
102. Marquardt T., Shirasaki R, Ghosh S, Andrews SE, Carter N, Hunter T., Pfaff SL. 2005. Coexpressed EphA receptors and ephrin-A ligands mediate opposing actions on growth cone navigation from distinct membrane domains. Cell 121: 127-139.
103. Marston D. J, Dickinson S, Nobes CD. 2003. Rac-dependent trans-endocytosis of ephrin-Bs regulates Eph-ephrin contact repulsion. Nat Cell Biol 5: 879-888.
104. McKay MM, Morrison DK. 2007. Integrating signals from RTKs to ERK/MAPK. Oncogene 26: 3113-3121.
105. Meier C., Anastasiadou S, Knoll B. 2011. Ephrin-A5 suppresses neurotrophin evoked neuronal motility, ERK activation and gene expression. PLoS ONE 6: e26089.
106. Mellitzer G., Xu QL, Wilkinson DG. 1999. Eph receptors and ephrins restrict cell intermingling and communication. Nature 400: 77-81.
107. Menges C. W, McCance DJ. 2008. Constitutive activation of the Raf-MAPK pathway causes negative feedback inhibition of Ras-PI3K-AKT and cellular arrest through the EphA2 receptor. Oncogene 27: 2934-2940.
108. Miao H., Wei BR, Peehl DM, Li Q, Alexandrou T, Schelling JR, Rhim JS, Sedor JR, Burnett E, Wang BC. 2001. Activation of EphA receptor tyrosine kinase inhibits the Ras/ MAPK pathway. Nat Cell Biol 3: 527-530.
109. Miao H., Li DQ, Mukherjee A, Guo H, Petty A, Cutter J, Basilion J. P, Sedor J, Wu J, Danielpour D, et al. 2009. EphA2 mediates ligand-dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt. Cancer Cell 16: 9-20.
110. Minami M., Koyama T, Wakayama Y, Fukuhara S, Mochizuki N. 2011. Ephrin-A/EphA signal facilitates insulinlike growth factor-I-induced myogenic differentiation through suppression of the Ras/extracellular signal-regulated kinase 1/2 cascade in myoblast cell lines. Mol Biol Cell 22: 3508-3519.
111. Moeller M. L, Shi Y, Reichardt LF, Ethell IM. 2006. EphB receptors regulate dendritic spine morphogenesis through the recruitment/phosphorylation of focal adhesion kinase and RhoA activation. J Biol Chem 281: 1587-1598.
112. Murai K. K, Nguyen LN, Irie F, Yamaguchi Y, Pasquale EB. 2003. Control of hippocampal dendritic spine morphology through ephrin-A3/EphA4 signaling. NatNeurosci 6: 153-160.
113. Naj A. C, Jun G, Beecham GW, Wang LS, Vardarajan BN, Buros J., Gallins PJ, Buxbaum JD, Jarvik GP, Crane PK, et al. 2011. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet 43: 436-441.
114. Nakada M., Drake KL, Nakada S, Niska JA, Berens ME. 2006. Ephrin-B3 ligand promotes glioma invasion through activation of Rac1. Cancer Res 66: 8492-8500.
115. Nie D, DiNardo A, Han JM, Baharanyi H, Kramvis I, Huynh T, Dabora S, Codeluppi S, Pandolfi PP, Pasquale EB, et al. 2010. Tsc2-Rheb signaling regulates EphA-mediated axon guidance. Nat Neurosci 13: 163-172.
116. Nievergall E., Janes PW, Stegmayer C, Vail ME, Haj FG, Teng SW, Neel BG, Bastiaens PI, Lackmann M. 2010. PTP1B regulates Eph receptor function and trafficking. J Cell Biol 191: 1189-1203.
117. Noberini R., Lamberto I, Pasquale EB. 2012a. Targeting Eph receptors with peptides and small molecules: Progress and challenges. Semin Cell Dev Biol 23: 51-57.
118. Noberini R., Rubio de la Torre E, Pasquale EB. 2012b. Profiling Eph receptor expression in cells and tissues: A targeted mass spectrometry approach. Cell Adh Migr 6: 102-112.
119. Oricchio E., Nanjangud G, Wolfe AL, Schatz JH, Mavrakis KJ, Jiang M, Liu X, Bruno J, Heguy A, Olshen AB, et al. 2011. The eph-receptor A7 is a soluble tumor suppressor for follicular lymphoma. Cell 147: 554-564.
120. Palmer A., Zimmer M, Erdmann KS, EulenburgV, Porthin A, Heumann R., Deutsch U, Klein R. 2002. Ephrin-B phosphorylation and reverse signaling: Regulation by Src kinases and PTP-BL phosphatase. Mol Cell 9: 725-737.
121. Park E. C, Cho GS, Kim GH, Choi SC, Han JK. 2011. The involvement of Eph-Ephrin signaling in tissue separation and convergence during Xenopus gastrulation movements. Dev Biol 350: 441-450.
122. Parri M., Buricchi F, Taddei ML, Giannoni E, Raugei G, Ramponi G., Chiarugi P. 2005. Ephrin-A1 repulsive response is regulated by an EphA2 tyrosine phosphatase. J Biol Chem 280: 34008-34018.
123. Parrinello S., Napoli I, Ribeiro S, Digby PW, Fedorova M, Parkinson D. B, Doddrell RD, Nakayama M, Adams RH, Lloyd A.C. 2010. EphB signaling directs peripheral nerve regeneration through Sox2-dependent Schwann cell sorting. Cell 143: 145-155.
124. Pasquale E.B. 2004. Eph-ephrin promiscuity is now crystal clear. Nat Neurosci 7: 417-418.
125. Pasquale E.B. 2005. Eph receptor signalling casts a wide net on cell behaviour. Nat Rev Mol Cell Biol 6: 462-475.
126. Pasquale E.B. 2008. Eph-ephrin bidirectional signaling in physiology and disease. Cell 133: 38-52.
127. Pasquale E.B. 2010. Eph receptors and ephrins in cancer: Bidirectional signalling and beyond. Nat Rev Cancer 10: 165-180.
128. Peifer M., Fernandez-Cuesta L, Sos ML, George J, Seidel D, Kasper L. H, Plenker D, Leenders F, Sun R, Zander T, et al. 2012. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet 44: 1104-1110.
129. Penzes P., Beeser A, Chernoff J, Schiller MR, Eipper BA, Mains R. E, Huganir RL. 2003. Rapid induction of dendritic spine morphogenesis by trans-synaptic Ephrin-BEphB receptor activation of the Rho-GEF Kalirin. Neuron 37: 263-274.
130. Picco V., Hudson C, Yasuo H. 2007. Ephrin-Eph signalling drives the asymmetric division of notochord/neural precursors in Ciona embryos. Development 134: 1491-1497.
131. Pitulescu M. E, Adams RH. 2010. Eph/ephrin molecules-A hub for signaling and endocytosis. Genes Dev 24: 2480-2492.
132. Poliakov A., Cotrina ML, Pasini A, Wilkinson DG. 2008. Regulation of EphB2 activation and cell repulsion by feedback control of the MAPK pathway. J Cell Biol 183: 933-947.
133. Prickett T. D, Agrawal NS, Wei X, Yates KE, Lin JC, Wunderlich JR, Cronin JC, Cruz P, Rosenberg SA, Samuels Y. 2009. Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat Genet 41: 1127-1132.
134. Qiu R, Wang J, TsarkW, Lu Q. 2010. Essential role of PDZRGS3 in the maintenance of neural progenitor cells. Stem Cells 28: 1602-1610.
135. Richter M, Murai KK, Bourgin C, Pak D, Pasquale EB. 2007. The EphA4 receptor regulates neuronal morphology through SPAR-mediated inactivation of Rap GTPases. J Neurosci 27: 14205-14215.
136. Riedl J. A, Brandt DT, Batlle E, Price LS, Clevers H, Bos JL. 2005. Down-regulation of Rap1 activity is involved in ephrin-B1-induced cell contraction. Biochem J 389: 465-469.
137. Rohani N., Canty L, Luu O, Fagotto F, Winklbauer R. 2011. Ephrin-B/EphB signaling controls embryonic germ layer separation by contact-induced cell detachment. PLoS Biol 9: e1000597.
138. Sahin M., Greer PL, Lin MZ, Poucher H, Eberhart J, Schmidt S, Wright TM, Shamah SM, O'Connell S, Cowan CW, et al. 2005. Eph-dependent tyrosine phosphorylation of ephexin1 modulates growth cone collapse. Neuron 46: 191-204.
139. Salaita K., Groves JT. 2010. Roles of the cytoskeleton in regulating EphA2 signals. Commun Integr Biol 3: 454-457.
140. Sawamiphak S., Seidel S, Essmann CL, Wilkinson GA, Pitulescu ME, Acker T, Acker-Palmer A. 2010. Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis. Nature 465: 487-491.
141. Schlessinger J. 2013. Receptor tyrosine kinases: Legacy of the first two decades. Cold Spring Harb Perspect Biol doi: 10.1101/cshperspect.a008912.
142. Segura I., Essmann CL, Weinges S, Acker-Palmer A. 2007. Grb4 and GIT1 transduce ephrin-B reverse signals modulating spine morphogenesis and synapse formation. Nat Neurosci 10: 301-310.
143. Seiradake E., Harlos K, Sutton G, Aricescu AR, Jones EY. 2010. An extracellular steric seeding mechanism for Eph-ephrin signaling platform assembly. Nat Struct Mol Biol 17: 398-402.
144. Senturk A., Pfennig S, Weiss A, Burk K, Acker-Palmer A. 2011. Ephrin Bs are essential components of the Reelin pathway to regulate neuronal migration. Nature 472: 356-360.
145. Shamah S. M, Lin MZ, Goldberg JL, Estrach S, Sahin M, Hu L, Bazalakova M, Neve RL, Corfas G, Debant A, et al. 2001. EphA receptors regulate growth cone dynamics through the novel guanine nucleotide exchange factor ephexin. Cell 105: 233-244.
146. Sharma S. V, Bell DW, Settleman J, Haber DA. 2007. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7: 169-181.
147. Shi W., Levine M. 2008. Ephrin signaling establishes asymmetric cell fates in an endomesoderm lineage of the Ciona embryo. Development 135: 931-940.
148. Shi L., Fu WY, Hung KW, Porchetta C, Hall C, Fu AK, Ip NY. 2007. a2-chimaerin interacts with EphA4 and regulates EphA4-dependent growth cone collapse. Proc Natl Acad Sci 104: 16347-16352.
149. Shiels A., Bennett TM, Knopf HL, Maraini G, Li A, Jiao X, Hejtmancik J.F. 2008. The EPHA2 gene is associated with cataracts linked to chromosome 1p. Mol Vis 14: 2042-2055.
150. Shintani T., Ihara M, Sakuta H, Takahashi H, Watakabe I, Noda M. 2006. Eph receptors are negatively controlled by protein tyrosine phosphatase receptor typeO. NatNeurosci 9: 761-769.
151. Singla N., Erdjument-Bromage H, Himanen JP, Muir TW, Nikolov D.B. 2011. A semisynthetic Eph receptor tyrosine kinase provides insight into ligand-induced kinase activation. Chem Biol 18: 361-371.
152. Skaggs B. J, Gorre ME, Ryvkin A, Burgess MR, Xie Y, Han Y, Komisopoulou E., Brown LM, Loo JA, Landaw EM, et al. 2006. Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants. Proc Natl Acad Sci 103: 19466-19471.
153. Solanas G., Cortina C, Sevillano M, Batlle E. 2011. Cleavage of E-cadherin by ADAM10 mediates epithelial cell sorting downstream of EphB signalling. Nat Cell Biol 13: 1100-1107.
154. Stahl S., Branca RM, Efazat G, Ruzzene M, Zhivotovsky B, Lewensohn R., Viktorsson K, Lehtio J. 2011. Phosphoproteomic profiling of NSCLC cells reveals that ephrin B3 regulates pro-survival signaling through Akt1-mediated phosphorylation of the EphA2 receptor. J Proteome Res 10: 2566-2578.
155. Stein E., Lane AA, Cerretti DP, Schoecklmann HO, Schroff AD, Van Etten RL, Daniel TO. 1998. Eph receptors discriminate specific ligand oligomers to determine alternative signaling complexes, attachment, and assembly responses. Genes Dev 12: 667-678.
156. Tandon M., Vemula SV, Mittal SK. 2011. Emerging strategies for EphA2 receptor targeting for cancer therapeutics. Expert Opin Ther Targets 15: 31-51.
157. Tolias K. F, Bikoff JB, Kane CG, Tolias CS, Hu L, Greenberg ME. 2007. The Rac1 guanine nucleotide exchange factor Tiam1 mediates EphB receptor-dependent dendritic spine development. Proc Natl Acad Sci 104: 7265-7270.
158. Truitt L., Freywald A. 2011. Dancing with the dead: Eph receptors and their kinase-null partners. Biochem Cell Biol 89: 115-129.
159. Udayakumar D., Zhang G, Ji Z, Njauw CN, Mroz P, Tsao H. 2011. EphA2 is a critical oncogene in melanoma. Oncogene 30: 4921-4929.
160. Van Hoecke A, Schoonaert L, Lemmens R, Timmers M, Staats K. A, Laird AS, Peeters E, Philips T, Goris A, Dubois B, et al. 2012. EPHA4 is a disease modifier of amyotrophic lateral sclerosis in animal models and in humans. Nat Med 18: 1418-1422.
161. Vindis C., Cerretti DP, Daniel TO, Huynh-Do U. 2003. EphB1 recruits c-Src and p52Shc to activate MAPK/ ERK and promote chemotaxis. J Cell Biol 162: 661-671.
162. Wagner MJ, Stacey MM, Liu BA, Pawson T. 2013. Molecular mechanisms of SH2-and PTB-domain containing proteins in receptor tyrosine kinase signaling. Cold Spring Harb Perspect Biol doi: 10.1101/cshperspect.a008987.
163. Wahl S., Barth H, Ciossek T, Aktories K, Mueller BK. 2000. Ephrin-A5 induces collapse of growth cones by activating Rho and Rho kinase. J Cell Biol 149: 263-270.
164. Wakayama Y., Miura K, Sabe H, Mochizuki N. 2011. Ephrin-A1-EphA2 signal induces compaction and polarization of Madin-Darby canine kidney cells by inactivating ezrin through negative regulation of RhoA. J Biol Chem 286: 44243-44253.
165. Walker-Daniels J, Riese DJ 2nd, Kinch MS. 2002. c-Cbldependent EphA2 protein degradation is induced by ligand binding. Mol Cancer Res 1: 79-87.
166. Wang Y, Nakayama M, Pitulescu ME, Schmidt TS, Bochenek ML, Sakakibara A, Adams S, Davy A, DeutschU, LuthiU, et al. 2010. Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis. Nature 465: 483-486.
167. Wegmeyer H., Egea J, Rabe N, Gezelius H, Filosa A, Enjin A, Varoqueaux F., Deininger K, Schnutgen F, Brose N, et al. 2007. EphA4-dependent axon guidance is mediated by the RacGAP a2-chimaerin. Neuron 55: 756-767.
168. Wei S., Xu G, Bridges LC, Williams P, White JM, DeSimone DW. 2010. ADAM13 induces cranial neural crest by cleaving class B ephrins and regulating Wnt signaling. Dev Cell 19: 345-352.
169. Wimmer-Kleikamp SH, Janes PW, Squire A, Bastiaens PI, Lackmann M. 2004. Recruitment of Eph receptors into signaling clusters does not require ephrin contact. J Cell Biol 164: 661-666.
170. Wimmer-Kleikamp SH, Nievergall E, Gegenbauer K, Adikari S, Mansour M, Yeadon T, Boyd AW, Patani NR, Lackmann M. 2008. Elevated protein tyrosine phosphatase activity provokes Eph/ephrin-facilitated adhesion of pre-B leukemia cells. Blood 112: 721-732.
171. Wu C., Qiu R, Wang J, Zhang H, Murai K, Lu Q. 2009. ZHX2 Interacts with Ephrin-B and regulates neural progenitor maintenance in the developing cerebral cortex. J Neurosci 29: 7404-7412.
172. Wybenga-Groot LE, Baskin B, Ong SH, Tong JF, Pawson T, Sicheri F. 2001. Structural basis for autoinhibition of the EphB2 receptor tyrosine kinase by the unphosphorylated juxtamembrane region. Cell 106: 745-757.
173. Wykosky J., Gibo DM, Stanton C, DebinskiW. 2005. EphA2 as a novel molecular marker and target in glioblastoma multiforme. Mol Cancer Res 3: 541-551.
174. Wykosky J., Palma E, Gibo DM, Ringler S, Turner CP, Debinski W. 2008. Soluble monomeric Ephrin-A1 is released from tumor cells and is a functional ligand for the EphA2 receptor. Oncogene 27: 7260-7273.
175. Xiao Z., Carrasco R, Kinneer K, Sabol D, Jallal B, Coats S, Tice D.A. 2012. EphB4 promotes or suppresses Ras/ MEK/ERK pathway in a context-dependent manner: Implications for EphB4 as a cancer target. Cancer Biol Ther 13: 630-637.
176. Xu N. J, Henkemeyer M. 2009. Ephrin-B3 reverse signaling through Grb4 and cytoskeletal regulators mediates axon pruning. Nat Neurosci 12: 268-276.
177. Xu J., Litterst C, Georgakopoulos A, Zaganas I, Robakis NK. 2009. Peptide EphB2/CTF2 generated by the g-secretase processing of EphB2 receptor promotes tyrosine phosphorylation and cell surface localization of N-methyl-Daspartate receptors. J Biol Chem 284: 27220-27228.
178. Yamaguchi Y., Pasquale EB. 2004. Eph receptors in the adult brain. Curr Opin Neurobiol 14: 288-296.
179. Yang N. Y, Fernandez C, Richter M, Xiao Z, Valencia F, Tice DA, Pasquale EB. 2011. Cross talk of the EphA2 receptor with a serine/threonine phosphatase suppresses the AktmTORC1 pathway in cancer cells. Cell Signal 23: 201-212.
180. Yin Y., Yamashita Y, Noda H, Okafuji T, Go MJ, Tanaka H. 2004. EphA receptor tyrosine kinases interact with coexpressed ephrin-A ligands in cis. Neurosci Res 48: 285-296.
181. Yoo S., Kim Y, Noh H, Lee H, Park E, Park S. 2011. Endocytosis of EphA receptors is essential for the proper development of the retinocollicular topographic map. EMBOJ 30: 1593-1607.
182. Yumoto N, Wakatsuki S, Kurisaki T, Hara Y, Osumi N, Frisen J, Sehara-Fujisawa A. 2008. Meltrin b/ADAM19 interacting with EphA4 in developing neural cells participates in formation of the neuromuscular junction. PLoS ONE 3: e3322.
183. Zafeiriou D. I, Pavlidou EL, Vargiami E. 2011. Diverse clinical and genetic aspects of craniofrontonasal syndrome. Pediatr Neurol 44: 83-87.
184. Zelinski D. P, Zantek ND, Stewart JC, Irizarry AR, Kinch MS. 2001. EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res 61: 2301-2306.
185. Zhang J., Yang PL, Gray NS. 2009a. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 9: 28-39.
186. Zhang T, Hua R, XiaoW, Burdon KP, Bhattacharya SS, Craig JE, Shang D, Zhao X, Mackey DA, Moore AT, et al. 2009b. Mutations of the EPHA2 receptor tyrosine kinase gene cause autosomal dominant congenital cataract. Hum Mutat 30: E603-611.
187. Zhuang G., Hunter S, Hwang Y, Chen J. 2007. Regulation of EphA2 receptor endocytosis by SHIP2 lipid phosphatase via phosphatidylinositol 3-Kinase-dependent Rac1 activation. J Biol Chem 282: 2683-2694.
188. Zhuang G., SongW, Amato K, Hwang Y, Lee K, Boothby M, Ye F., Guo Y, Shyr Y, Lin L, et al. 2012. Effects of cancerassociated EPHA3 mutations on lung cancer. J Natl Cancer Inst 104: 1182-1197.
189. Zimmer M., Palmer A, Kohler J, Klein R. 2003. EphB-ephrin-B bi-directional endocytosis terminates adhesion allowing contact mediated repulsion. Nat Cell Biol 5: 869-878.
190. Zisch A. H, Pasquale EB. 1997. The Eph family: A multitude of receptors that mediate cell recognition signals. Cell Tissue Res 290: 217-226.
191. Zisch A. H, Pazzagli C, Freeman AL, Schneller M, Hadman M, Smith JW, Ruoslahti E, Pasquale EB. 2000. Replacing two conserved tyrosines of the EphB2 receptor with glutamic acid prevents binding of SH2 domains without abrogating kinase activity and biological responses. Oncogene 19: 177-187.
192. Zwick E., Bange J, Ullrich A. 2002. Receptor tyrosine kinases as targets for anticancer drugs. Trends Mol Med 8: 17-23.